首页> 外文期刊>有機合成化学協会誌 >Constrained Peptides in Drug Discovery and Development
【24h】

Constrained Peptides in Drug Discovery and Development

机译:药物发现和发育中的约束肽

获取原文
获取原文并翻译 | 示例
           

摘要

Constrained peptides, namely macrocyclic and stapled peptides, are receiving increasing attention as a promising class of compounds for the inhibition of protein-protein interactions (PPI). The current state of peptide therapeutics is discussed, including their merits and challenges, as well as recent technological developments that have enabled a new era in peptide research and development. The technology behind PeptiDream's Peptide Discovery Platform System (PDPS) is described, showing how it can be used to rapidly generate libraries of constrained peptides and obtain detailed SAR information. This technology can provide, with a high rate of success, potent peptide ligands that may be developed as drug candidates themselves, utilized in peptide-drug conjugates (PDC), or converted into small molecule drug leads. The outlook for the field of constrained peptides and their use in the clinic is also described.
机译:限制性肽,即大环和订书钉肽,作为一类有希望抑制蛋白质-蛋白质相互作用(PPI)的化合物,正受到越来越多的关注。讨论了肽疗法的现状,包括它们的优点和挑战,以及使肽研究和开发进入新时代的最新技术发展。描述了肽流的肽发现平台系统(PDPS)背后的技术,展示了如何使用它快速生成受限肽库并获得详细的SAR信息。这项技术可以提供高成功率的有效肽配体,这些配体本身可以开发为候选药物,用于肽-药物缀合物(PDC),或转化为小分子药物先导物。本文还对限制性肽及其临床应用进行了展望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号